Fig. 2From: Proliferative potential and resistance to immune checkpoint blockade in lung cancer patientsResults for cell proliferation as an independent biomarker. a) Proportion of 120 NSCLC patients for cell proliferation by tertiles of poorly, moderately, and highly proliferative. b) Proportion of 120 NSCLC patients positive or negative for PD-L1 IHC using a cut-off of tumor proportion score of ≥50% as a positive result. c) Proportion of 120 NSCLC patients positive or negative for PD-L1 IHC using a cut-off of tumor proportion score of ≥1% as a positive result. d) Prevalence for all combinations of strongly positive PD-L1 (TPS ≥ 50%) cases and proliferation status. e) Prevalence for all combinations of PD-L1 and proliferation status for weakly positive PD-L1 cases (TPS ≥ 1 and < 50%). f) Prevalence for all PD-L1 negative (TPS < 1%) cases and proliferation status. Number and p values are reportedBack to article page